Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir

George, EC; Bucciardini, R; Richert, L; Dedes, N; Fragola, V; Nieuwkerk, P; Spire, B; ... NEAT 001/ANRS 143 Study Group, ; + view all George, EC; Bucciardini, R; Richert, L; Dedes, N; Fragola, V; Nieuwkerk, P; Spire, B; Volny-Anne, A; West, B; Molina, J-M; Horban, A; Fox, J; Pozniak, A; Vella, S; Termote, M; Raffi, F; NEAT 001/ANRS 143 Study Group, ; - view fewer (2018) Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir. Journal of Acquired Immune Deficiency Syndromes , 79 (4) pp. 519-526. 10.1097/QAI.0000000000001844 . Green open access

http://bit.ly/2FuknC1